Assessment of the Multiple Sclerosis Severity Score and the Age-Related Multiple Sclerosis Severity Score as health indicators in a population-based cohort
According to the MSSS and ARMSSS, the severity of MS in our area is mild, and these instruments are consistent. These measures could be reliable health outcome measures.
Authors
- Isabel León (ORCID: https://orcid.org/0000-0002-4352-0730)
- Lucía Romero (ORCID: https://orcid.org/0000-0001-8054-0565)
- Pablo Arroyo-Pereiro (ORCID: https://orcid.org/0000-0003-0632-4850)
- Elisabet Matas (ORCID: https://orcid.org/0009-0005-6137-6583)
- Laura Bau (ORCID: https://orcid.org/0000-0003-2221-8759)
- Antonio Martı́nez-Yélamos (ORCID: https://orcid.org/0000-0002-3725-0180)
- Albert Muñoz‐Vendrell (ORCID: https://orcid.org/0000-0001-8221-865X)
- Sergio Martínez‐Yélamos (ORCID: https://orcid.org/0000-0001-9889-2040)
Institutions
- Bellvitge University Hospital (ES)
- Institut d'Investigació Biomédica de Bellvitge (ES)
- Universitat de Barcelona (ES)
Publication Details
- Journal
- Neurological Sciences
- Published
- 2024-09-17
- DOI
- https://doi.org/10.1007/s10072-024-07767-3
- Citations
- 3
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.27
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- Sanofi
- Biogen
- Teva Pharmaceutical Industries
- Celgene
- Centres de Recerca de Catalunya
- Generalitat de Catalunya
- H. Lundbeck A/S
- Neuraxpharm
- Allergan